SEC Form 4 · accession 0001179110-18-010936
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eldon C. Mayer III
Officer — EVP & Chief Commercial Officer
Period of report
Aug 23, 2018
Accepted (ET)
Aug 27, 2018 · 7:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 23, 2018 | P | 100,000 | $2.8232 | A | 115,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions ranging from $2.78 to $2.86 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each such separate price.
- F2Includes 15,000 shares that were purchased by the Reporting Person under the Issuer's Employee Stock Purchase Plan, in increments of 5,000 shares, on June 30, 2017, December 29, 2017 and June 29, 2018.